Head to Head Contrast: La Jolla Pharmaceutical (LJPC) and Its Rivals
La Jolla Pharmaceutical (NASDAQ: LJPC) is one of 282 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare La Jolla Pharmaceutical to similar companies based on the strength of its dividends, valuation, earnings, profitability, institutional ownership, analyst recommendations and risk.
This is a summary of recent recommendations for La Jolla Pharmaceutical and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|La Jolla Pharmaceutical||0||0||6||0||3.00|
|La Jolla Pharmaceutical Competitors||809||3177||11503||230||2.71|
Earnings & Valuation
This table compares La Jolla Pharmaceutical and its rivals revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|La Jolla Pharmaceutical||$620,000.00||-$78.18 million||-6.80|
|La Jolla Pharmaceutical Competitors||$286.20 million||$34.74 million||137.81|
La Jolla Pharmaceutical’s rivals have higher revenue and earnings than La Jolla Pharmaceutical. La Jolla Pharmaceutical is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
La Jolla Pharmaceutical has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500. Comparatively, La Jolla Pharmaceutical’s rivals have a beta of 7.35, indicating that their average stock price is 635% more volatile than the S&P 500.
Insider and Institutional Ownership
48.9% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 25.5% of La Jolla Pharmaceutical shares are held by company insiders. Comparatively, 17.3% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares La Jolla Pharmaceutical and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|La Jolla Pharmaceutical||N/A||-88.55%||-78.19%|
|La Jolla Pharmaceutical Competitors||-4,860.82%||-431.24%||-39.50%|
About La Jolla Pharmaceutical
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). It has initiated a Phase III trial of LJPC-501 for the treatment of CRH, called the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS) Phase III trial. LJPC-401 is its formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is its next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections, as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
Receive News & Stock Ratings for La Jolla Pharmaceutical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical Company and related stocks with our FREE daily email newsletter.